KRAS and neoplasm: The tumor microenvironment (TME) in NSCLC, featuring regulatory T cells and myeloid-derived suppressor cells, can create an immunosuppressive landscape that enhances PD-L1 expression, complicating responses to both KRAS G12C inhibitors and PD-L1 therapies [11,12].